Literature DB >> 23404338

Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour.

Oscar Hernández-Hernández1, Céline Guiraud-Dogan, Géraldine Sicot, Aline Huguet, Sabrina Luilier, Esther Steidl, Stefanie Saenger, Elodie Marciniak, Hélène Obriot, Caroline Chevarin, Annie Nicole, Lucile Revillod, Konstantinos Charizanis, Kuang-Yung Lee, Yasuhiro Suzuki, Takashi Kimura, Tohru Matsuura, Bulmaro Cisneros, Maurice S Swanson, Fabrice Trovero, Bruno Buisson, Jean-Charles Bizot, Michel Hamon, Sandrine Humez, Guillaume Bassez, Friedrich Metzger, Luc Buée, Arnold Munnich, Nicolas Sergeant, Geneviève Gourdon, Mário Gomes-Pereira.   

Abstract

Myotonic dystrophy type 1 is a complex multisystemic inherited disorder, which displays multiple debilitating neurological manifestations. Despite recent progress in the understanding of the molecular pathogenesis of myotonic dystrophy type 1 in skeletal muscle and heart, the pathways affected in the central nervous system are largely unknown. To address this question, we studied the only transgenic mouse line expressing CTG trinucleotide repeats in the central nervous system. These mice recreate molecular features of RNA toxicity, such as RNA foci accumulation and missplicing. They exhibit relevant behavioural and cognitive phenotypes, deficits in short-term synaptic plasticity, as well as changes in neurochemical levels. In the search for disease intermediates affected by disease mutation, a global proteomics approach revealed RAB3A upregulation and synapsin I hyperphosphorylation in the central nervous system of transgenic mice, transfected cells and post-mortem brains of patients with myotonic dystrophy type 1. These protein defects were associated with electrophysiological and behavioural deficits in mice and altered spontaneous neurosecretion in cell culture. Taking advantage of a relevant transgenic mouse of a complex human disease, we found a novel connection between physiological phenotypes and synaptic protein dysregulation, indicative of synaptic dysfunction in myotonic dystrophy type 1 brain pathology.

Entities:  

Mesh:

Year:  2013        PMID: 23404338      PMCID: PMC3580270          DOI: 10.1093/brain/aws367

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  69 in total

Review 1.  The synaptic vesicle cycle.

Authors:  Thomas C Sudhof
Journal:  Annu Rev Neurosci       Date:  2004       Impact factor: 12.449

2.  Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy.

Authors:  Robert J Osborne; Xiaoyan Lin; Stephen Welle; Krzysztof Sobczak; Jason R O'Rourke; Maurice S Swanson; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2009-02-17       Impact factor: 6.150

3.  Decreased cerebral glucose utilization in myotonic dystrophy.

Authors:  M Fiorelli; D Duboc; B M Mazoyer; J Blin; B Eymard; M Fardeau; Y Samson
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

4.  Human growth hormone co-transfection assay to study molecular mechanisms of neurosecretion in PC12 cells.

Authors:  Shuzo Sugita
Journal:  Methods       Date:  2004-08       Impact factor: 3.608

5.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

6.  Opposite changes in glutamatergic and GABAergic transmission underlie the diffuse hyperexcitability of synapsin I-deficient cortical networks.

Authors:  Michela Chiappalone; Silvia Casagrande; Mariateresa Tedesco; Flavia Valtorta; Pietro Baldelli; Sergio Martinoia; Fabio Benfenati
Journal:  Cereb Cortex       Date:  2008-11-19       Impact factor: 5.357

Review 7.  The neuropsychopharmacology of fronto-executive function: monoaminergic modulation.

Authors:  T W Robbins; A F T Arnsten
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

8.  In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation.

Authors:  Melanie K Tallent; Neal Varghis; Yuliya Skorobogatko; Lisa Hernandez-Cuebas; Kelly Whelan; David J Vocadlo; Keith Vosseller
Journal:  J Biol Chem       Date:  2008-11-11       Impact factor: 5.157

9.  Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activity.

Authors:  Martin C Schweizer; Markus S H Henniger; Inge Sillaber
Journal:  PLoS One       Date:  2009-01-29       Impact factor: 3.240

10.  Mice deficient for the synaptic vesicle protein Rab3a show impaired spatial reversal learning and increased explorative activity but none of the behavioral changes shown by mice deficient for the Rab3a regulator Gdi1.

Authors:  Patrizia D'Adamo; David P Wolfer; Caroline Kopp; Irene Tobler; Daniela Toniolo; Hans-Peter Lipp
Journal:  Eur J Neurosci       Date:  2004-04       Impact factor: 3.386

View more
  28 in total

1.  Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1.

Authors:  Jeffrey R Wozniak; Bryon A Mueller; Kelvin O Lim; Laura S Hemmy; John W Day
Journal:  J Neurol Sci       Date:  2014-04-13       Impact factor: 3.181

2.  Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.

Authors:  Siham Ait Benichou; Dominic Jauvin; Thiéry De Serres-Bérard; Marion Pierre; Karen K Ling; C Frank Bennett; Frank Rigo; Genevieve Gourdon; Mohamed Chahine; Jack Puymirat
Journal:  Gene Ther       Date:  2022-01-25       Impact factor: 5.250

3.  Myotonic dystrophy RNA toxicity alters morphology, adhesion and migration of mouse and human astrocytes.

Authors:  Diana M Dincã; Louison Lallemant; Anchel González-Barriga; Noémie Cresto; Sandra O Braz; Géraldine Sicot; Laure-Elise Pillet; Hélène Polvèche; Paul Magneron; Aline Huguet-Lachon; Hélène Benyamine; Cuauhtli N Azotla-Vilchis; Luis E Agonizantes-Juárez; Julie Tahraoui-Bories; Cécile Martinat; Oscar Hernández-Hernández; Didier Auboeuf; Nathalie Rouach; Cyril F Bourgeois; Geneviève Gourdon; Mário Gomes-Pereira
Journal:  Nat Commun       Date:  2022-07-04       Impact factor: 17.694

4.  Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting.

Authors:  Francisco-Jose Fernandez-Gomez; Fanny Jumeau; Maxime Derisbourg; Sylvie Burnouf; Hélène Tran; Sabiha Eddarkaoui; Hélène Obriot; Virginie Dutoit-Lefevre; Vincent Deramecourt; Valérie Mitchell; Didier Lefranc; Malika Hamdane; David Blum; Luc Buée; Valérie Buée-Scherrer; Nicolas Sergeant
Journal:  J Vis Exp       Date:  2014-04-10       Impact factor: 1.355

5.  Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.

Authors:  Mei Wang; Wen-Chin Weng; Lauren Stock; Diana Lindquist; Ana Martinez; Genevieve Gourdon; Nikolai Timchenko; Mike Snape; Lubov Timchenko
Journal:  Mol Cell Biol       Date:  2019-10-11       Impact factor: 4.272

Review 6.  RNA-protein interactions in unstable microsatellite diseases.

Authors:  Apoorva Mohan; Marianne Goodwin; Maurice S Swanson
Journal:  Brain Res       Date:  2014-04-04       Impact factor: 3.252

7.  Epiretinal membrane: a treatable cause of visual disability in myotonic dystrophy type 1.

Authors:  Hannah M Kersten; Richard H Roxburgh; Nicholas Child; Philip J Polkinghorne; Chris Frampton; Helen V Danesh-Meyer
Journal:  J Neurol       Date:  2013-10-17       Impact factor: 4.849

8.  A comprehensive atlas of fetal splicing patterns in the brain of adult myotonic dystrophy type 1 patients.

Authors:  Max J F Degener; Remco T P van Cruchten; Brittney A Otero; Eric T Wang; Derick G Wansink; Peter A C 't Hoen
Journal:  NAR Genom Bioinform       Date:  2022-03-08

9.  Synaptopathy Mechanisms in ALS Caused by C9orf72 Repeat Expansion.

Authors:  Agnes L Nishimura; Natalia Arias
Journal:  Front Cell Neurosci       Date:  2021-06-01       Impact factor: 5.505

10.  Transcriptome alterations in myotonic dystrophy frontal cortex.

Authors:  Brittney A Otero; Kiril Poukalov; Ryan P Hildebrandt; Charles A Thornton; Kenji Jinnai; Harutoshi Fujimura; Takashi Kimura; Katharine A Hagerman; Jacinda B Sampson; John W Day; Eric T Wang
Journal:  Cell Rep       Date:  2021-01-19       Impact factor: 9.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.